Ming Hsieh, our founder, served as the manager of our predecessor, Fulgent Therapeutics LLC (“Fulgent LLC”), from its inception in June 2011 until September 2016, was appointed as our director and Chief Executive Officer upon our incorporation in May 2016 and was appointed as Chair of our Board in September 2016 in connection with our initial public offering. Mr. Hsieh also served as the President of the Company from its inception to May 2022. Prior to founding our Company, Mr. Hsieh served as Chief Executive Officer, President and Chairperson of the board of directors of Cogent, Inc., a biometric identification services and products company he co-founded in 1990, which was acquired by 3M in 2010. Prior to his tenure at Cogent, Mr. Hsieh founded and served as Vice President of AMAX Technology from 1987 to 1990. Mr. Hsieh currently serves on the board of directors of Fortinet, Inc., a network security company traded on the Nasdaq Global Select Market. Mr. Hsieh received a B.S.E.E. from the University of Southern California in 1983 and an M.S.E.E. from the University of Southern California in 1984, as well as honorary doctoral degrees from the University of Southern California in 2010 and the University of West Virginia in 2011. Mr. Hsieh has served as a trustee at the University of Southern California since 2007 and at Fudan University in China since 2011. In 2015, Mr. Hsieh was elected to the National Academy of Engineering. In 2017, Mr. Hsieh was elected to the National Academy of Inventors. Mr. Hsieh was selected to serve on our Board based on his extensive management experience; his knowledge of our business, culture, and operations as our founder, his engineering expertise; and his service for and leadership of our Company since inception.

Dr. Ray Yin, co-founder of Fulgent Therapeutics (later split into Fulgent Genetics and Fulgent Pharma), is the president and Chief Scientific Officer of Fulgent Pharma. Dr. Yin also founded ANP Technologies, which is a leading provider of nanobiotechnology based diagnostic and therapeutic products and intermediates. Prior to that, Dr. Yin worked at the U.S. Army Research Laboratory managing its nanobiotechnology for chemical and biological defense program, as well as serving as a scientific advisor on various DoD/Joint Service/DARPA/NATO programs and committees. Dr. Yin is a world-class expert, a prolific inventor, and an accomplished entrepreneur in the nanobiotechnology area, receiving a variety of U.S. and international patents and awards. Some of the major awards include three consecutive U.S. Army R&D Achievement Awards, an AAPS Annual Award, and a National Tibbetts Award. As the Principal Investigator, Dr. Yin successfully led the development of a number of nanotechnology-based products from concept creation to final product fielding/commercialization. These include the first nanotechnology-based rapid multiplexed biological agent detection system currently fielded by DoD, the commercialization of an FDA EUA authorized COVID-19 antigen rapid test supported under the NIH/RADx initiative, as well as a first-in-class nano-drug delivery system that has achieved U.S. FDA DMF status with two clinical stage drugs currently under development. Dr. Yin received his Ph.D. in chemistry from the University of Southern California.

Dr. James Burke has led oncology drug development programs for over 20 years, ranging from classic chemotherapeutic agents to gene therapy for cancer. Notably, at CG Oncology, Dr Burke's leadership extended from initial first in human studies of cretostimogene (AKA CG0070, an oncolytic adenovirus targeting bladder cancer), to pivotal phase 2-3 approval targeted trials, to the most successful NASDAQ biotech IPO of 2024. Prior to CG Oncology, he served as Chief Medical Officer​ at Jennerex, Sillajen, and Turnstone Bio. Dr. Burke currently is spearheading the next generation vaccinia oncolytic virus program at Kalivir Immunotherapeutics. A UCSF trained hematologist and oncologist, he has extensive experience in treating patients with cancer and hematologic disorders as an investigator and research director in the clinical setting.

Dr. Lin Wang is Chief Operating Officer of Fulgent Pharma, leading Pharma operations to support drug development R&D, CMC, preclinical, clinical and regulatory workstreams. Dr. Wang started his professional career at DuPont Central Research and Development, with 34 issued U.S. patents as co-inventor during his seven-year tenure as PI and R&D leader. He became Ph.D. Recruiting Manager of DuPont Corporate HR, in charge of DuPont's corporate Ph.D. and science recruiting. He was a member of DuPont Corporate China Growth Strategy Team and was later appointed Lab Director of DuPont China R&D Center, a corporate-level R&D organization, where he was in charge of Center start up and operation, supporting product commercialization. He then became VP and operation head of Tianjin International Joint Academy of Biotechnology and Medicine (TJAB), a national-level biopharmaceutical incubator that incubated several successful companies, including CanSino Biologics (a HKEX and SSE listed company; CASBF for OTC), one of the only 10 companies in the world that successfully developed a SARS-CoV2 vaccine, which was authorized by the World Health Organization (WHO) during COVID-19 pandemic. Dr. Wang received his Ph.D. and postdoc training in chemistry from the University of Southern California and Caltech, respectively. He was a member of DuPont Corporate Technology Council and was invited by Shanghai Municipality as an advisory councilor for Shanghai Science & Technology Development. He is a co-founder and board member of the Delaware Chinese American Association.